10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2019 | |||
Consolidated Statement of Income | |||
Period Ending Dec 31, 2019 10-K (Filed: Feb 26, 2020) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | |
| Sales | $ 46,840 | 42,294 | 40,122 |
| Costs, Expenses and Other | |||
| Cost of sales | 14,112 | 13,509 | 12,912 |
| Selling, general and administrative | 10,615 | 10,102 | 10,074 |
| Research and development | 9,872 | 9,752 | 10,339 |
| Restructuring costs | 638 | 632 | 776 |
| Other (income) expense, net | 139 | (402) | (500) |
| Total Costs, Expenses and Other | 35,376 | 33,593 | 33,601 |
| Income Before Taxes | 11,464 | 8,701 | 6,521 |
| Taxes on Income | 1,687 | 2,508 | 4,103 |
| Net Income | 9,777 | 6,193 | 2,418 |
| Less: Net (Loss) Income Attributable to Noncontrolling Interests | (66) | (27) | 24 |
| Net Income Attributable to Merck & Co., Inc. | 9,843 | 6,220 | 2,394 |
| Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) | 3.84 | 2.34 | 0.88 |
| Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) | 3.81 | 2.32 | 0.87 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2019 | |||
Consolidated Statement of Comprehensive Income | |||
Period Ending Dec 31, 2019 10-K (Filed: Feb 26, 2020) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | |
| Net Income Attributable to Merck & Co., Inc. | $ 9,843 | 6,220 | 2,394 |
| Other Comprehensive (Loss) Income Net of Taxes: | |||
| Net unrealized (loss) gain on derivatives, net of reclassifications | (135) | 297 | |
| Net unrealized (loss) gain on derivatives, net of reclassifications | (446) | ||
| Net unrealized gain (loss) on investments, net of reclassifications | 96 | (10) | (58) |
| Benefit plan net (loss) gain and prior service (cost) credit, net of amortization | (705) | (425) | 419 |
| Cumulative translation adjustment | 96 | (223) | 401 |
| Other comprehensive income (loss), net of taxes | (648) | (361) | 316 |
| Comprehensive Income Attributable to Merck & Co., Inc. | 9,195 | 5,859 | 2,710 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2019 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2019 10-K (Filed: Feb 26, 2020) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | |
| Cash Flows from Operating Activities | |||
| Net income | $ 9,777 | 6,193 | 2,418 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 3,652 | 4,519 | 4,676 |
| Intangible asset impairment charges | 1,040 | 296 | 646 |
| Charge for the acquisition of Peloton Therapeutics, Inc. | 993 | 0 | 0 |
| Charge for future payments related to collaboration license options | 0 | 650 | 500 |
| Provisional charge for one-time transition tax related to the enactment of U.S. tax legislation | 0 | 0 | 5,347 |
| Deferred income taxes | (556) | (509) | (2,621) |
| Share-based compensation | 417 | 348 | 312 |
| Other | 184 | 978 | 190 |
| Net changes in assets and liabilities: | |||
| Accounts receivable | 294 | (418) | 297 |
| Inventories | (508) | (911) | (145) |
| Trade accounts payable | 399 | 230 | 254 |
| Accrued and other current liabilities | 376 | (341) | (922) |
| Income taxes payable | (2,359) | 827 | (3,291) |
| Noncurrent liabilities | (237) | (266) | (123) |
| Other | (32) | (674) | (1,087) |
| Net Cash Provided by Operating Activities | 13,440 | 10,922 | 6,451 |
| Cash Flows from Investing Activities | |||
| Capital expenditures | (3,473) | (2,615) | (1,888) |
| Purchases of securities and other investments | (3,202) | (7,994) | (10,739) |
| Proceeds from sales of securities and other investments | 8,622 | 15,252 | 15,664 |
| Acquisition of Antelliq Corporation, net of cash acquired | (3,620) | 0 | 0 |
| Acquisition of Peloton Therapeutics, Inc., net of cash acquired | (1,040) | 0 | 0 |
| Other acquisitions, net of cash acquired | (294) | (431) | (396) |
| Other | 378 | 102 | 38 |
| Net Cash (Used in) Provided by Investing Activities | (2,629) | 4,314 | 2,679 |
| Cash Flows from Financing Activities | |||
| Net change in short-term borrowings | (3,710) | 5,124 | (26) |
| Payments on debt | 0 | (4,287) | (1,103) |
| Proceeds from issuance of debt | 4,958 | 0 | 0 |
| Purchases of treasury stock | (4,780) | (9,091) | (4,014) |
| Dividends paid to stockholders | (5,695) | (5,172) | (5,167) |
| Proceeds from exercise of stock options | 361 | 591 | 499 |
| Other | 5 | (325) | (195) |
| Net Cash Used in Financing Activities | (8,861) | (13,160) | (10,006) |
| Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash | 17 | (205) | 457 |
| Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash | 1,967 | 1,871 | (419) |
| Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $2 million of restricted cash at January 1, 2019 included in Other Assets) | 7,967 | 6,096 | |
| Cash, Cash Equivalents and Restricted Cash at End of Year (includes $258 million of restricted cash at December 31, 2019 included in Other Assets - see Note 6) | 9,934 | 7,967 | 6,096 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
MERCK & CO., INC. | ||
Ticker: MRK Fiscal Year: 2019 | ||
Consolidated Balance Sheet | ||
Period Ending Dec 31, 2019 10-K (Filed: Feb 26, 2020) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2019 | Dec 31, 2018 | |
| Assets | ||
| Current Assets | ||
| Cash and cash equivalents | $ 9,676 | 7,965 |
| Short-term investments | 774 | 899 |
| Accounts receivable (net of allowance for doubtful accounts of $86 in 2019 and $119 in 2018) | 6,778 | 7,071 |
| Inventories (excludes inventories of $1,480 in 2019 and $1,417 in 2018 classified in Other assets - see Note 7) | 5,978 | 5,440 |
| Other current assets | 4,277 | 4,500 |
| Total current assets | 27,483 | 25,875 |
| Investments | 1,469 | 6,233 |
| Property, Plant and Equipment (at cost) | ||
| Land | 343 | 333 |
| Buildings | 11,989 | 11,486 |
| Machinery, equipment and office furnishings | 15,394 | 14,441 |
| Construction in progress | 5,013 | 3,355 |
| Property, plant and equipment (at cost) | 32,739 | 29,615 |
| Less: accumulated depreciation | 17,686 | 16,324 |
| Property, plant and equipment, net | 15,053 | 13,291 |
| Goodwill | 19,425 | 18,253 |
| Other Intangibles, Net | 14,196 | 13,104 |
| Other Assets | 6,771 | 5,881 |
| Total Assets | 84,397 | 82,637 |
| Liabilities and Equity | ||
| Current Liabilities | ||
| Loans payable and current portion of long-term debt | 3,610 | 5,308 |
| Trade accounts payable | 3,738 | 3,318 |
| Accrued and other current liabilities | 12,549 | 10,151 |
| Income taxes payable | 736 | 1,971 |
| Dividends payable | 1,587 | 1,458 |
| Total current liabilities | 22,220 | 22,206 |
| Long-Term Debt | 22,736 | 19,806 |
| Deferred Income Taxes | 1,470 | 1,702 |
| Other Noncurrent Liabilities | 11,970 | 12,041 |
| Merck & Co., Inc. Stockholders Equity | ||
| Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2019 and 2018 | 1,788 | 1,788 |
| Other paid-in capital | 39,660 | 38,808 |
| Retained earnings | 46,602 | 42,579 |
| Accumulated other comprehensive loss | (6,193) | (5,545) |
| Stockholders' equity before deduction for treasury stock | 81,857 | 77,630 |
| Less treasury stock, at cost: 1,038,087,496 shares in 2019 and 984,543,979 shares in 2018 | 55,950 | 50,929 |
| Total Merck & Co., Inc. stockholders equity | 25,907 | 26,701 |
| Noncontrolling Interests | 94 | 181 |
| Total equity | 26,001 | 26,882 |
| Total Liabilities and Equity | 84,397 | 82,637 |
| External Links | |
| MERCK & CO., INC. (MRK) Fiscal Year 2019 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |